PC
AVNR

Polar Capital’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Polar Capital’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-17,821
Closed -$60K – 296
2013
Q4 		$60K Buy
+17,821
New +$73.6K ﹤0.01% 265

Other funds holding AVNR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Polar Capital's AVNR Position: Q1 2014 in Review

Polar Capital sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2014, closing a stake of 17,821 shares — an estimated $60K sold.

Polar Capital first reported a position in AVNR in Q4 2013 and held it in 1 quarter. The position peaked at $60K in Q4 2013. 100 funds tracked by Wall St. Rank hold AVNR as of Q1 2014.

  • Polar Capital reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2014 after selling out during the quarter.
  • Polar Capital sold 17,821 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2014, an estimated $60K.
  • Polar Capital first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q4 2013 and held it in 1 quarter.
  • Polar Capital's AVANIR PHARMACEUTICALS, INC CL A position peaked at $60K in Q4 2013.
  • 100 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2014.

Based on Polar Capital's 13F filing for Q1 2014, filed 7 May 2014.